Delphine Davan, EMBA 2018, new VP at Medicenna
Delphine Davan, graduated from the McGill-HEC Montreal EMBA in 2018. She recently joined the Medicenna Therapeutics Corp team. as Vice President of Investor Relations and Corporate Communications.
Medicenna is a clinical stage immunotherapy company that uses directed evolution to generate engineered interleukins called Superkines that can modulate, fine-tune or amplify the immune system in order to combat the most challenging diseases and inspire hope in patients with unmet needs.
“The McGill-HEC Montréal EMBA has completed my Master’s in Cell Biology and my 15 years of experience in business development, mainly in the pharmaceutical industry.
During the program, I have developed a more strategic and structured approach, and also acquired a solid foundation in finance that allowed me to transition my role towards investor relations for biotech companies listed on the TSX and Nasdaq stock markets.”